Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide
NCT07819227 on ClinicalTrials.gov · last registry update 2026-09-28
A small phase 2 — 41 participants, against a typical 110. Completed 31 August 2026. semaglutide is already approved in the US for chronic kidney disease, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University Medical Center Groningen
- Sponsor type
- Other
- Enrollment
- 41
- Started
- 2025-02-11
- Primary completion
- 2026-08-31 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-14 | First seen in registry | Registered as COMPLETED, P2 |
Primary outcome
Proportion of patients with ≥30% reduction in urinary albumin:creatinine ratio (UACR) from baseline during monotherapy with finerenone or semaglutide or combined treatment with finerenone-semaglutide.
Conditions studied
Chronic Kidney Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.